Markets

bioAffinity Technologies To Present New Data On Sputum-Based Tests In Development To Characterize Lung Inflammation And Detect Multiple Protein Biomarkers Of Lung Inflammation At CHEST 2026

Oct 13, 2026 · 08:02 AM ET· updated 52m ago

Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targetsCompany advances research and development in diagnostic tests for major lung diseases

Why It Matters

bioAffinity is showing new research on a sputum test that spots lung inflammation. This means the company is making progress on a tool doctors might use someday.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BIAF3.46

-0.44 (-11.28%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.